초록 ▼

The invention concerns a composition containing at least an alkanolamide, optionally combined with at least a compound such as a metalloprotease inhibitor, a PKC inhibitor, an anti-inflammatory agent, a soothing agent, an immunosuppressor, an ion chelating agent, an oxazolin, an oxazolidinone and a

The invention concerns a composition containing at least an alkanolamide, optionally combined with at least a compound such as a metalloprotease inhibitor, a PKC inhibitor, an anti-inflammatory agent, a soothing agent, an immunosuppressor, an ion chelating agent, an oxazolin, an oxazolidinone and a carbamic acid derivative. The invention also concerns the use of such a composition as medicine, in particular its use for preventing or treating skin pathologies of allergic and/or inflammatory and/or irritative origin or resulting from a danger signal. The invention further concerns a method for cosmetic treatment of sensitive, irritated, intolerant, allergy-prone, ageing skin and/or mucosa exhibiting skin barrier disorder, or exhibiting non-pathological immunologic imbalance, which consists in applying such a composition on the skin and/or mucosa.

대표청구항 ▼

1. A method for treating conditions or disorders which comprises: inhibiting migration of dentritic cells, dermal dendrocytes, monocytes, lymphocytes, keratinocytes, mastocytes and endothelial cells in a living animal body exposed to an agent that induces the cutaneous immune response, by administer

1. A method for treating conditions or disorders which comprises: inhibiting migration of dentritic cells, dermal dendrocytes, monocytes, lymphocytes, keratinocytes, mastocytes and endothelial cells in a living animal body exposed to an agent that induces the cutaneous immune response, by administering to the living animal body an effective amount of a composition comprising AK100 at a concentration between 0.01 and 3% by weight, said AK100 having the following formula: and peptide extracts of lupin at a concentration between 0.1 to 3% by weight,wherein the conditions or disorders are selected from an allergic, an inflammatory, or an irritative reaction or pathology of the skin or mucosa due to a migration of Langerhans cells, a reaction or a pathology induced by chemical or metallic haptens, sensitive skin, atopic eczema, contact eczema, inflammatory dermatitis, irritative dermatitis, auto-immune diseases, or graft rejection. 2. The method of claim 1, wherein the migration of Langerhans cells in inhibited. 3. The method as claimed in claim 1, wherein the inflammatory dermatitis is psoriasis. 4. The method of claim 1, wherein the composition further comprises a compound chosen from the group constituted by PKC inhibitors, anti-inflammatory agents, soothing agents, immunosuppressors, ion chelating agents, oxazolines, oxazolidinones and derivatives of carbamic acid. 5. The method according to claim 1, wherein the AK100 is at a concentration of 0.1% weight and the peptide extracts of lupin is at a concentration of 2% by weight. 6. The method according to claim 1, wherein the cutaneous immune response induced by the agent comprises the migration of Langerhans cells followed by capture of a surface antigen, and wherein the Langerhans cells present the antigen to T cells. 7. The method according to claim 1, wherein the agent is an antigen. 8. The method according to claim 1, wherein the agent is an allergen. 9. The method according to claim 1, wherein the composition further comprises retinoids.